Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure
European Journal of Medical Research · 2024
DOI: 10.1186/s40001-024-01809-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Medical Research, 2024. Verfasst von Tianqing Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University, Hunan, China. Hauptthemen laut MEDLINE: Heart Failure, Iron, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Postgraduate Research and Innovation Project of Hunan Province, Scientific Research Project of Hunan Provincial Health Commission.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The progression of heart failure (HF) is complex and involves multiple regulatory pathways. Iron ions play a crucial supportive role as a cofactor for important proteins such as hemoglobin, myoglobin, oxidative respiratory chain, and DNA synthetase, in the myocardial energy metabolism process. In recent years, numerous studies have shown that HF is associated with iron dysmetabolism, and deficiencies in iron and overload of iron can both lead to the development of various myocarditis diseases, which ultimately progress to HF. Iron toxicity and iron metabolism may be key targets for the diagnosis, treatment, and prevention of HF. Some iron chelators (such as desferrioxamine), antioxidants (such as ascorbate), Fer-1, and molecules that regulate iron levels (such as lactoferrin) have been shown to be effective in treating HF and protecting the myocardium in multiple studies. Additionally, certain natural compounds can play a significant role by mediating the imbalance of iron-related signaling pathways and expression levels. Therefore, this review not only summarizes the basic processes of iron metabolism in the body and the mechanisms by which they play a role in HF, with the aim of providing new clues and considerations for the treatment of HF, but also summarizes recent studies on natural chemical components that involve ferroptosis and its role in HF pathology, as well as the mechanisms by which naturally occurring products regulate ferroptosis in HF, with the aim of providing reference information for the development of new ferroptosis inhibitors and lead compounds for the treatment of HF in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University, Hunan, China.
- People's Hospital of Ningxiang City, Ningxiang City, China.
- Department of Cardiology, Changde Hospital, Xiangya School of Medicine, Central South University, Hunan, China. geliangqing@163.com.
Förderung
- Postgraduate Research and Innovation Project of Hunan Province
- Scientific Research Project of Hunan Provincial Health Commission
Zitieren
APA
Zhang, T., Luo, L., He, Q., Xiao, S., Li, Y., Chen, J., Qin, T., Xiao, Z., & Ge, Q. (2024). Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure. European Journal of Medical Research. https://doi.org/10.1186/s40001-024-01809-4
Vancouver
Zhang T, Luo L, He Q, Xiao S, Li Y, Chen J, et al. Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure. European Journal of Medical Research. 2024. doi:10.1186/s40001-024-01809-4
BibTeX
@article{Zhang2024,
author = {Zhang, Tianqing and Luo, Li and He, Qi and Xiao, Sijie and Li, Yuwei and Chen, Junpeng and Qin, Tao and Xiao, Zhenni and Ge, Qingliang},
title = {Research advances on molecular mechanism and natural product therapy of iron metabolism in heart failure},
journal = {European Journal of Medical Research},
year = {2024},
doi = {10.1186/s40001-024-01809-4}
}
EUVIMED